Cancer Type/Condition: Lymphoma, Hodgkin lymphoma, child
Stage/Subtype: recurrent/refractory childhood Hodgkin lymphoma
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NCI, Other
Protocol IDs: 09-073, NCT00928018
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI
Protocol IDs: FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI
Protocol IDs: NCI-01-C-0125F, NCT00020592
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
12.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 100
Sponsor: Other
Protocol IDs: BCM-H-12472, H 12472, BCM-ACHE, NCT00056966
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-110, SUN08-01, NCT00704054
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-2230.00, 2230.00, IR-6771, NCT00789776
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: CHNY-01-501, AAAA5185, NCT00802113
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: J0844, JHM IRB # NA_00017193, NCT00809276
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 74
Sponsor: NCI
Protocol IDs: 080051, 08-C-0051, NCT00923910
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-99-H-0050, NCT00003838
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI
Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1667.00, NCI-H02-0098, NCT00049504
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 5 to 75
Sponsor: NCI
Protocol IDs: RPCI-RP-0105, NCT00053989, RP 01-05
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: ID02-407, NCT00067002
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695
|
